Adicet Bio Inc Stock News

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 5.36% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antige

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -24.44% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antige

Today, we take a look at Adicet Bio for the first time. The company is pioneering what it hopes will be among the next wave of CAR-T therapies and is advancing its lead candidate.

Adicet Bio, Inc. (ACET) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here is how Adicet Bio, Inc. (ACET) and Catalyst Biosciences, Inc. (CBIO) have performed compared to their sector so far this year.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antige

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen

Adicet Bio, Inc. (ACET) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -6.82% and 17.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Adicet Bio (ACET) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Adicet Bio, Inc. (ACET) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The company's platform is based on gamma delta 1 T cells, which have been major investor attention recently. The next data update from the above ADI-001 FIH study is expected in mid this year (likely